Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12989556 | 0.86 | CYP2D6 (0.46) | GABRR1 | |
| SCHEMBL24916247 | 0.86 | CES2 (0.36) | TDP1 | |
| SCHEMBL12134777 | 0.81 | — | — | |
| SCHEMBL3468187 | 0.80 | — | — | |
| SCHEMBL8424785 | 0.79 | CA1 (0.34) | EPHX1TDP1 | |
| SCHEMBL18099944 | 0.79 | CA14 (0.36) | FCER2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12055917 | 0.78 | CYP1A2 (0.46) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL26169813 | 0.78 | FCER2 (0.36) | FCER2 | |
| SCHEMBL12532948 | 0.77 | TDP1 (0.38) | EPHX1TDP1 | |
| SCHEMBL13056255 | 0.77 | GABRR1 (0.37) | EPHX1TDP1GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374073-A1 | DIMERIC MILLA IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365628-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1, PDCD1LG2 | FCER2 1574/4885PKM 3031/4885EPHX1 4722/4885 |
| US-20230374073-A1 | DIMERIC MILLA IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | FCER2 1331/4885PKM 3422/4885EPHX1 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.